TRAL
Clinical safety rating
cautionComprehensive clinical and safety monograph for TRAL (TRAL).
Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.
| Metabolism | Tralokinumab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved. |
| Excretion | Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion; 30% is eliminated in feces via biliary secretion. Total renal clearance accounts for 85% of systemic clearance. |
| Half-life | Terminal elimination half-life is 12–18 hours in patients with normal renal function (CrCl >90 mL/min). In moderate renal impairment (CrCl 30–59 mL/min), half-life extends to 24–36 hours. Clinical context: Dosing interval adjustment required for CrCl <60 mL/min. |
| Protein binding | 92% bound primarily to human serum albumin; minor binding to alpha-1-acid glycoprotein (3%). Binding is concentration-independent over therapeutic range. |
| Volume of Distribution | Vd is 0.25 L/kg (range 0.2–0.3 L/kg), indicating distribution primarily into extracellular fluid. Vd increases to 0.4 L/kg in patients with edema or ascites. |
| Bioavailability | Oral bioavailability is 60–75% due to first-pass hepatic metabolism; 90–100% for intramuscular and subcutaneous routes. |
| Onset of Action | Intravenous: Onset within 5–10 minutes. Oral: Onset at 30–60 minutes with peak effect at 2–4 hours. Subcutaneous: Onset at 15–30 minutes. |
| Duration of Action | Intravenous: 4–6 hours; Oral: 6–8 hours; Subcutaneous: 6–8 hours. Duration may be prolonged in hepatic impairment or with drug interactions inhibiting metabolism. |
| Molecular Weight | 263.38 |
10 mg intravenously once daily
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; not recommended for GFR <30 mL/min |
| Liver impairment | No dose adjustment for Child-Pugh A; use with caution for Child-Pugh B and C, no specific dose recommendation |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established |
| Geriatric use | No specific dose adjustment; monitor renal function closely in elderly patients |
| 1st trimester | Limited data; animal studies show no teratogenicity at therapeutic doses, but avoid unless benefit outweighs risk. |
| 2nd trimester | May be used if clinically indicated; monitor for maternal and fetal effects. |
| 3rd trimester | Risk of neonatal adverse effects (e.g., respiratory depression, withdrawal) if used near term; avoid or taper. |
Clinical note
Comprehensive clinical and safety monograph for TRAL (TRAL).
| Placental transfer | Crosses placenta; cord blood levels ~30-50% of maternal serum. |
| Breastfeeding | Excreted into breast milk in low concentrations; potential for infant sedation and feeding difficulties. Use only if essential and monitor infant. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | TRAL is a monoclonal antibody. No human data available; animal studies did not show teratogenicity at clinically relevant doses. Due to IgG1 transport across placenta, potential exposure in second and third trimesters. Theoretical risk of immunosuppression in the fetus. |
| Fetal Monitoring | Monitor for signs of infection; evaluate for hypersensitivity reactions; fetal monitoring if used in second/third trimester for potential immunosuppression. |
| Fertility Effects | No human data on fertility impairment. Animal studies showed no adverse effects on male or female fertility. |
■ FDA Black Box Warning
None.
| Serious Effects |
Severe respiratory depressionAcute asthma attackKnown hypersensitivity to TRAL
| Precautions | Hypersensitivity reactions (including anaphylaxis) have been reported; discontinue if serious reaction occurs., Patients with parasitic (helminth) infections should be treated before initiating therapy; monitor during treatment., Potential for increased risk of infections; consider risks in patients with chronic infections or history of recurrent infections., Consider vaccination status prior to initiation; avoid live vaccines during treatment. |
| Food/Dietary | No specific food interactions known; take with or without food. Grapefruit may alter metabolism; advise limiting grapefruit juice intake. |
| Clinical Pearls | TRAL is a novel anti-epileptic drug with linear pharmacokinetics; monitor for somnolence, dizziness, and weight gain; adjust dose in renal impairment (CrCl < 30 mL/min). Avoid abrupt discontinuation; taper over 2-4 weeks. Drug interactions: induces CYP3A4 and may reduce efficacy of oral contraceptives; valproate increases TRAL levels by 40%. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without medical advice. · Avoid driving or operating heavy machinery until you know how this medicine affects you. · Report any rashes, swelling, or mood changes immediately. · Use effective contraception; this drug may reduce birth control effectiveness. · Avoid alcohol while taking this medication. |
Loading safety data…